Eisai and Biogen have announced that the FDA has accepted their supplemental Biologics License Application for monthly LEQEMBI IV maintenance dosing.

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly’s real-time, streaming news feed keeps individual…

Read More: https://thefly.com/permalinks/entry.php/id3930954/BIIB-Eisai-Biogen-say-FDA-accepted-sBLA-for-monthly-LEQEMBI-IV-maintenance-dosing1717976528